Joud Hajjar1,2, Danielle Guffey3, Charles G Minard3, Jordan S Orange4,5. 1. Section of Immunology, Allergy and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. joud.hajjar@bcm.edu. 2. Texas Children's Hospital, Houston, TX, USA. joud.hajjar@bcm.edu. 3. Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA. 4. Section of Immunology, Allergy and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 5. Texas Children's Hospital, Houston, TX, USA.
Abstract
INTRODUCTION: Patients with primary immunodeficiency (PID) often report fatigue, yet this symptom has not been studied in PID. Fatigue affects 6-7.5% of healthy adults. The goal of this study is to estimate the prevalence of fatigue in patients with PID and investigate its associated factors. METHODS: We analyzed 2537 PID patients registered in USIDNET to determine responses to the field "fatigue" in the core registry form. Demographics, immune phenotypes, and comorbid conditions were compared between fatigued and non-fatigued patients to identify relevant associations and potential drivers. A focused analysis was performed for patients with predominantly antibody deficiency disorders (PADs). RESULTS: Fatigue was reported in 25.9% (95% CI 23.7-28.3) of PAD patients, compared to 6.4% (95% CI 4.9-8.2) of non-PAD. Patients with common variable immunodeficiency (CVID) had the highest prevalence of fatigue (p < 0.001) among all PID diagnoses. Other factors that were associated with a higher rate of fatigue among PAD patients included female sex, higher BMI, depression, bronchiectasis, and autoimmunity. Additionally, fatigued PAD patients had lower absolute lymphocyte, CD3, CD4, and CD8 counts compared to non-fatigued patients. CONCLUSION: Our findings suggest that fatigue is overrepresented in PAD patients. Prospective studies to estimate prevalence, risk factors, and fatigue etiology in PID are warranted, so therapeutic interventions can be considered.
INTRODUCTION:Patients with primary immunodeficiency (PID) often report fatigue, yet this symptom has not been studied in PID. Fatigue affects 6-7.5% of healthy adults. The goal of this study is to estimate the prevalence of fatigue in patients with PID and investigate its associated factors. METHODS: We analyzed 2537 PID patients registered in USIDNET to determine responses to the field "fatigue" in the core registry form. Demographics, immune phenotypes, and comorbid conditions were compared between fatigued and non-fatigued patients to identify relevant associations and potential drivers. A focused analysis was performed for patients with predominantly antibody deficiency disorders (PADs). RESULTS:Fatigue was reported in 25.9% (95% CI 23.7-28.3) of PAD patients, compared to 6.4% (95% CI 4.9-8.2) of non-PAD. Patients with common variable immunodeficiency (CVID) had the highest prevalence of fatigue (p < 0.001) among all PID diagnoses. Other factors that were associated with a higher rate of fatigue among PAD patients included female sex, higher BMI, depression, bronchiectasis, and autoimmunity. Additionally, fatigued PADpatients had lower absolute lymphocyte, CD3, CD4, and CD8 counts compared to non-fatigued patients. CONCLUSION: Our findings suggest that fatigue is overrepresented in PAD patients. Prospective studies to estimate prevalence, risk factors, and fatigue etiology in PID are warranted, so therapeutic interventions can be considered.
Authors: Anne M Fink; Rosalia C Gonzalez; Tadeusz Lisowski; Maria Pini; Giamila Fantuzzi; Wayne C Levy; Mariann R Piano Journal: J Card Fail Date: 2012-09 Impact factor: 5.712
Authors: Perry Skeath; Shanti Norris; Vani Katheria; Jonathan White; Karen Baker; Dan Handel; Esther Sternberg; John Pollack; Hunter Groninger; Jayne Phillips; Ann Berger Journal: Qual Health Res Date: 2013-07-17
Authors: Sokratis Dinos; Bernadette Khoshaba; Deborah Ashby; Peter D White; James Nazroo; Simon Wessely; Kamaldeep S Bhui Journal: Int J Epidemiol Date: 2009-04-06 Impact factor: 7.196
Authors: Per Wågström; Åsa Nilsdotter-Augustinsson; Mats Nilsson; Janne Björkander; Charlotte Dahle; Sofia Nyström Journal: Front Immunol Date: 2022-01-10 Impact factor: 7.561
Authors: Lisanne M A Janssen; Paul Bassett; Thomas Macken; Jolanda van Esch; Hans Pruijt; Arnoud Knoops; Markus Sköld; Antony Parker; Jolanda de Vries; Esther de Vries Journal: Front Immunol Date: 2018-10-15 Impact factor: 7.561
Authors: Linde N Nijhof; Marco van Brussel; Esther M Pots; Raphaële R L van Litsenburg; Elise M van de Putte; Joris M van Montfrans; Sanne L Nijhof Journal: J Clin Immunol Date: 2021-03-17 Impact factor: 8.317